Trial Outcomes & Findings for A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder (NCT NCT03375203)

Last Updated: 2025-04-29

Results Overview

Change in LPS was measured on Night 1 by PSG. LPS is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep. The LPS change from baseline on Night 1 was calculated as (LPS at Night 1 minus Baseline LPS). Negative changes in LPS indicated improvement.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

365 participants

Primary outcome timeframe

Baseline and Night 1

Results posted on

2025-04-29

Participant Flow

Total of 365 participants were randomized and 364 participants were treated. 1 participant was randomized in error, never received any study drug and was excluded from the analyses. Among 364 treated participants,1 participant randomized to JNJ-42847922 10 mg group, received 5 mg of JNJ-42847922 and was summarized under 5 mg group for safety analyses, and under 10 mg dose group for all other analyses.

Participant milestones

Participant milestones
Measure	Placebo Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Overall Study STARTED	75	72	74	71	73
Overall Study COMPLETED	69	68	72	69	69
Overall Study NOT COMPLETED	6	4	2	2	4

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Overall Study Protocol Violation	0	0	1	0	0
Overall Study Adverse Event	2	3	0	2	2
Overall Study Withdrawal by Subject	3	0	1	0	2
Overall Study Non-compliance with study drug	1	0	0	0	0
Overall Study Randomized, not treated.	0	1	0	0	0

Baseline Characteristics

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=74 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	Total n=364 Participants Total of all reporting groups
Age, Continuous	58.6 years STANDARD_DEVIATION 11.49 • n=5 Participants	56.9 years STANDARD_DEVIATION 13.85 • n=7 Participants	57.6 years STANDARD_DEVIATION 12.9 • n=5 Participants	57.6 years STANDARD_DEVIATION 11.88 • n=4 Participants	58.5 years STANDARD_DEVIATION 12.03 • n=21 Participants	57.8 years STANDARD_DEVIATION 12.4 • n=10 Participants
Age, Customized Children (2-11 years)	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Age, Customized Adolescents (12-17 years)	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Age, Customized Adults (18-64 years)	50 Participants n=5 Participants	45 Participants n=7 Participants	48 Participants n=5 Participants	47 Participants n=4 Participants	48 Participants n=21 Participants	238 Participants n=10 Participants
Age, Customized From 65 to 84 years	25 Participants n=5 Participants	26 Participants n=7 Participants	26 Participants n=5 Participants	24 Participants n=4 Participants	25 Participants n=21 Participants	126 Participants n=10 Participants
Age, Customized 85 years and over	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Sex: Female, Male Female	45 Participants n=5 Participants	48 Participants n=7 Participants	51 Participants n=5 Participants	50 Participants n=4 Participants	52 Participants n=21 Participants	246 Participants n=10 Participants
Sex: Female, Male Male	30 Participants n=5 Participants	23 Participants n=7 Participants	23 Participants n=5 Participants	21 Participants n=4 Participants	21 Participants n=21 Participants	118 Participants n=10 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	13 Participants n=5 Participants	13 Participants n=7 Participants	10 Participants n=5 Participants	7 Participants n=4 Participants	10 Participants n=21 Participants	53 Participants n=10 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	62 Participants n=5 Participants	58 Participants n=7 Participants	63 Participants n=5 Participants	64 Participants n=4 Participants	63 Participants n=21 Participants	310 Participants n=10 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=10 Participants
Race (NIH/OMB) Asian	8 Participants n=5 Participants	5 Participants n=7 Participants	7 Participants n=5 Participants	4 Participants n=4 Participants	6 Participants n=21 Participants	30 Participants n=10 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	3 Participants n=4 Participants	0 Participants n=21 Participants	4 Participants n=10 Participants
Race (NIH/OMB) Black or African American	11 Participants n=5 Participants	15 Participants n=7 Participants	20 Participants n=5 Participants	18 Participants n=4 Participants	9 Participants n=21 Participants	73 Participants n=10 Participants
Race (NIH/OMB) White	54 Participants n=5 Participants	49 Participants n=7 Participants	46 Participants n=5 Participants	45 Participants n=4 Participants	57 Participants n=21 Participants	251 Participants n=10 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants

PRIMARY outcome

Timeframe: Baseline and Night 1

Population: Full analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Latency to Persistent Sleep (LPS) as Measured by Polysomnography (PSG) on Night 1	-15.24 Minutes Standard Deviation 78.547 • Interval 78.547 to	-29.92 Minutes Standard Deviation 49.049 • Interval 49.049 to	-49.49 Minutes Standard Deviation 53.216 • Interval 53.216 to	-47.69 Minutes Standard Deviation 48.423 • Interval 48.423 to	-40.74 Minutes Standard Deviation 54.395 • Interval 54.395 to

SECONDARY outcome

Timeframe: Baseline and over first 6 hours on Night 1

PSG was used to measure the time to wake after initial sleep onset (WASO) over the first 6 hours on Night 1. Negative changes in WASO indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Wake After Sleep Onset (WASO) Over the First 6 Hours as Measured by PSG on Night 1	-15.05 Minutes Standard Deviation 57.485 • Interval 57.485 to	-22.70 Minutes Standard Deviation 45.904 • Interval 45.904 to	-42.57 Minutes Standard Deviation 40.011 • Interval 40.011 to	-44.69 Minutes Standard Deviation 42.823 • Interval 42.823 to	-29.04 Minutes Standard Deviation 46.779 • Interval 46.779 to

SECONDARY outcome

Timeframe: Baseline and Night 13

LPS was measured on Night 13 by PSG. LPS is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch recorded as sleep. Negative changes in LPS indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=69 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in LPS as Measured by PSG on Night 13	-23.74 Minutes Standard Deviation 61.790 • Interval 61.79 to	-27.12 Minutes Standard Deviation 54.726 • Interval 54.726 to	-53.99 Minutes Standard Deviation 60.292 • Interval 60.292 to	-41.19 Minutes Standard Deviation 59.713 • Interval 59.713 to	-30.94 Minutes Standard Deviation 60.236 • Interval 60.236 to

SECONDARY outcome

Timeframe: Baseline and over first 6 hours on Night 13

PSG was used to measure the time to wake after initial sleep onset (WASO) over the first 6 hours on Night 13. Negative changes in WASO indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=69 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=68 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in WASO Over the First 6 Hours as Measured by PSG on Night 13	-17.80 Minutes Standard Deviation 52.369 • Interval 52.369 to	-14.63 Minutes Standard Deviation 57.207 • Interval 57.207 to	-30.74 Minutes Standard Deviation 52.835 • Interval 52.835 to	-38.40 Minutes Standard Deviation 53.661 • Interval 53.661 to	-20.22 Minutes Standard Deviation 46.465 • Interval 46.465 to

SECONDARY outcome

Timeframe: Baseline, Over 6 hours on Nights 1 and 13

TST is defined as the total sleep time in minutes. The total sleep time is the total amount of sleep time scored during the total recording time. Positive changes in TST indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Total Sleep Time (TST) as Measured by PSG Over 6 Hours on Nights 1 and 13 Night 1	25.50 Minutes Standard Deviation 72.146	43.26 Minutes Standard Deviation 50.771	76.47 Minutes Standard Deviation 50.711	80.49 Minutes Standard Deviation 56.216	53.70 Minutes Standard Deviation 57.688
Change From Baseline in Total Sleep Time (TST) as Measured by PSG Over 6 Hours on Nights 1 and 13 Night 13	33.16 Minutes Standard Deviation 71.488	39.80 Minutes Standard Deviation 66.556	66.03 Minutes Standard Deviation 62.995	67.66 Minutes Standard Deviation 66.254	35.84 Minutes Standard Deviation 64.950

SECONDARY outcome

Timeframe: Baseline, Over 8 hours on Nights 1 and 13

TST is defined as the total sleep time in minutes. The total sleep time is the total amount of sleep time scored during the total recording time. Positive changes in TST indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Total Sleep Time (TST) as Measured by PSG Over 8 Hours on Nights 1 and 13 Night 13	38.45 Minutes Standard Deviation 83.177	45.72 Minutes Standard Deviation 72.640	64.84 Minutes Standard Deviation 77.358	64.27 Minutes Standard Deviation 82.377	39.26 Minutes Standard Deviation 77.773
Change From Baseline in Total Sleep Time (TST) as Measured by PSG Over 8 Hours on Nights 1 and 13 Night 1	37.03 Minutes Standard Deviation 86.539	47.85 Minutes Standard Deviation 64.499	81.20 Minutes Standard Deviation 60.607	81.07 Minutes Standard Deviation 71.581	63.88 Minutes Standard Deviation 59.115

SECONDARY outcome

Timeframe: Baseline, Nights 1 and 13

Sleep efficiency was measured as the total sleep time divided by the total time in bed (that is, the number of hours from the beginning of the Polysomnography recording to the end of the recording) (in percentage). Positive changes in SE indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Sleep Efficiency (SE) Measured by PSG on Nights 1 and 13 Night 13	7.99 Percentage of efficient sleep Standard Deviation 17.322	9.51 Percentage of efficient sleep Standard Deviation 15.154	13.67 Percentage of efficient sleep Standard Deviation 16.037	13.56 Percentage of efficient sleep Standard Deviation 17.199	8.27 Percentage of efficient sleep Standard Deviation 16.323
Change From Baseline in Sleep Efficiency (SE) Measured by PSG on Nights 1 and 13 Night 1	7.74 Percentage of efficient sleep Standard Deviation 18.031	10.18 Percentage of efficient sleep Standard Deviation 12.818	16.92 Percentage of efficient sleep Standard Deviation 12.626	16.86 Percentage of efficient sleep Standard Deviation 14.963	13.29 Percentage of efficient sleep Standard Deviation 12.317

SECONDARY outcome

Timeframe: Baseline, Days 1 and 13 (Hours 1 to 8)

Polysomnography was used to measure the time to wake after initial sleep onset measured hourly on Day 1 and 13 from Hour 1 to Hour 8. WASO is measured during overnight sleep laboratory (PSG) assessment and defined as the duration of wakefulness from the onset of persistent sleep (that is, 10 consecutive minutes of sleep) over 8 hours of PSG assessment. Negative changes in WASO indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 7): Day 1	-5.01 Minutes Standard Deviation 22.247	-5.71 Minutes Standard Deviation 19.784	-3.84 Minutes Standard Deviation 16.756	-1.61 Minutes Standard Deviation 19.349	-6.15 Minutes Standard Deviation 13.756
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 3): Day 1	-5.57 Minutes Standard Deviation 18.316	-3.91 Minutes Standard Deviation 12.037	-11.05 Minutes Standard Deviation 13.272	-9.64 Minutes Standard Deviation 13.055	-9.62 Minutes Standard Deviation 14.141
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 3): Day 13	-5.70 Minutes Standard Deviation 17.681	-0.31 Minutes Standard Deviation 18.562	-8.10 Minutes Standard Deviation 12.446	-6.99 Minutes Standard Deviation 15.331	-5.12 Minutes Standard Deviation 18.140
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 4): Day 1	-5.33 Minutes Standard Deviation 17.109	-4.73 Minutes Standard Deviation 13.193	-9.67 Minutes Standard Deviation 14.495	-9.74 Minutes Standard Deviation 14.727	-6.23 Minutes Standard Deviation 16.471
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 4): Day 13	-5.49 Minutes Standard Deviation 18.185	-3.47 Minutes Standard Deviation 16.754	-9.57 Minutes Standard Deviation 14.483	-6.21 Minutes Standard Deviation 14.140	-7.00 Minutes Standard Deviation 15.727
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 5): Day 1	-3.36 Minutes Standard Deviation 22.284	-6.16 Minutes Standard Deviation 15.820	-7.53 Minutes Standard Deviation 14.371	-7.44 Minutes Standard Deviation 15.834	-4.34 Minutes Standard Deviation 16.150
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 5): Day 13	-4.96 Minutes Standard Deviation 22.597	-4.06 Minutes Standard Deviation 20.776	-5.34 Minutes Standard Deviation 20.232	-7.97 Minutes Standard Deviation 17.016	-5.03 Minutes Standard Deviation 16.306
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 6): Day 1	-1.06 Minutes Standard Deviation 17.258	-4.46 Minutes Standard Deviation 22.383	-5.44 Minutes Standard Deviation 17.510	-7.78 Minutes Standard Deviation 18.348	-1.46 Minutes Standard Deviation 19.965
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 6): Day 13	-4.69 Minutes Standard Deviation 19.658	-3.09 Minutes Standard Deviation 21.426	0.56 Minutes Standard Deviation 22.721	-7.37 Minutes Standard Deviation 20.872	0.84 Minutes Standard Deviation 20.768
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 7): Day 13	-3.57 Minutes Standard Deviation 21.828	-4.92 Minutes Standard Deviation 18.271	-1.50 Minutes Standard Deviation 21.145	1.16 Minutes Standard Deviation 23.642	-0.75 Minutes Standard Deviation 18.096
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 8): Day 1	-7.52 Minutes Standard Deviation 23.369	0.66 Minutes Standard Deviation 21.311	-0.65 Minutes Standard Deviation 22.278	1.25 Minutes Standard Deviation 22.046	-3.95 Minutes Standard Deviation 20.149
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 8): Day 13	-1.73 Minutes Standard Deviation 24.898	-0.63 Minutes Standard Deviation 20.118	1.88 Minutes Standard Deviation 23.845	1.24 Minutes Standard Deviation 20.858	-3.22 Minutes Standard Deviation 22.343
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 1): Day 1	-3.40 Minutes Standard Deviation 13.074	-3.55 Minutes Standard Deviation 10.510	-3.44 Minutes Standard Deviation 12.969	-6.37 Minutes Standard Deviation 14.213	-5.40 Minutes Standard Deviation 12.086
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 1): Day 13	0.43 Minutes Standard Deviation 12.083	-4.78 Minutes Standard Deviation 8.824	-7.05 Minutes Standard Deviation 14.569	-7.47 Minutes Standard Deviation 13.004	-4.90 Minutes Standard Deviation 11.821
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 2): Day 1	1.06 Minutes Standard Deviation 18.481	-5.72 Minutes Standard Deviation 11.817	-9.62 Minutes Standard Deviation 16.721	-10.82 Minutes Standard Deviation 13.658	-7.68 Minutes Standard Deviation 14.812
Change From Baseline in Wake After Sleep Onset (WASO) Measured Hourly on Days 1 and 13 From Hour 1 to Hour 8 WASO (hour 2):Day 13	1.11 Minutes Standard Deviation 18.504	-4.12 Minutes Standard Deviation 14.596	-9.04 Minutes Standard Deviation 17.034	-9.64 Minutes Standard Deviation 14.963	-4.37 Minutes Standard Deviation 16.883

SECONDARY outcome

Timeframe: Baseline, Over 6 hours on Day 1 and 13

Population: FAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies number of participants who were evaluable at specified time points.

PSG was used to measure the number of night-time awakenings over the first 6 hours after initial sleep onset. Negative changes in nNAW indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Number of Night-time Awakenings (nNAW) Over 6 Hours on Day 1 and 13 Day 1	-2.08 awakenings Standard Deviation 6.412	-0.87 awakenings Standard Deviation 7.224	0.14 awakenings Standard Deviation 7.385	-0.94 awakenings Standard Deviation 9.102	-1.14 awakenings Standard Deviation 8.727
Change From Baseline in Number of Night-time Awakenings (nNAW) Over 6 Hours on Day 1 and 13 Day 13	-2.02 awakenings Standard Deviation 6.928	0.93 awakenings Standard Deviation 7.769	-0.40 awakenings Standard Deviation 8.352	-2.13 awakenings Standard Deviation 7.542	-0.57 awakenings Standard Deviation 7.803

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure wake time during the total recording period. Negative changes in wake during total sleep period indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Wake During Total Sleep Period on Day 1 and 13 Day 1	-13.79 Minutes Standard Deviation 63.082	-27.47 Minutes Standard Deviation 58.188	-49.64 Minutes Standard Deviation 47.106	-52.25 Minutes Standard Deviation 40.828	-32.36 Minutes Standard Deviation 53.737
Change From Baseline in Wake During Total Sleep Period on Day 1 and 13 Day 13	-18.83 Minutes Standard Deviation 59.005	-19.79 Minutes Standard Deviation 60.626	-42.57 Minutes Standard Deviation 53.867	-41.95 Minutes Standard Deviation 64.846	-20.58 Minutes Standard Deviation 56.799

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure the time awake after final awakening to the end of the PSG period. Negative changes in wake after final awakening indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Wake After Final Awakening on Day 1 and 13 Day 1	-13.63 Minutes Standard Deviation 50.958	-0.28 Minutes Standard Deviation 29.552	2.80 Minutes Standard Deviation 38.492	7.21 Minutes Standard Deviation 45.189	-5.40 Minutes Standard Deviation 29.473
Change From Baseline in Wake After Final Awakening on Day 1 and 13 Day 13	-5.32 Minutes Standard Deviation 55.112	-0.39 Minutes Standard Deviation 31.519	12.42 Minutes Standard Deviation 62.515	5.62 Minutes Standard Deviation 48.641	-2.17 Minutes Standard Deviation 29.376

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure number of night time awakenings per hour. Negative changes in nNAW/hr indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Number of Night-time Awakenings Per Hour (nNAW/hr) on Day 1 and 13 Day 13	-0.34 Number of awakenings per hour Standard Deviation 1.155	0.16 Number of awakenings per hour Standard Deviation 1.295	-0.07 Number of awakenings per hour Standard Deviation 1.392	-0.36 Number of awakenings per hour Standard Deviation 1.257	-0.10 Number of awakenings per hour Standard Deviation 1.300
Change From Baseline in Number of Night-time Awakenings Per Hour (nNAW/hr) on Day 1 and 13 Day 1	-0.35 Number of awakenings per hour Standard Deviation 1.069	-0.14 Number of awakenings per hour Standard Deviation 1.204	0.02 Number of awakenings per hour Standard Deviation 1.231	-0.16 Number of awakenings per hour Standard Deviation 1.517	-0.19 Number of awakenings per hour Standard Deviation 1.455

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure the time to first awakening after sleep onset. Positive changes in time to first awakening after sleep indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=70 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Time to First Awakening After Sleep on Day 1 and 13 Day 1	12.05 Minutes Standard Deviation 57.535	10.71 Minutes Standard Deviation 61.015	23.11 Minutes Standard Deviation 73.749	53.90 Minutes Standard Deviation 92.802	35.63 Minutes Standard Deviation 74.617
Change From Baseline in Time to First Awakening After Sleep on Day 1 and 13 Day 13	11.08 Minutes Standard Deviation 45.714	32.13 Minutes Standard Deviation 70.549	33.12 Minutes Standard Deviation 71.826	48.92 Minutes Standard Deviation 88.909	27.55 Minutes Standard Deviation 75.080

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure REM duration (time to first REM period from sleep onset).

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Rapid Eye Movement (REM) Duration on Day 1 and 13 Day 1	10.32 Minutes Standard Deviation 24.366	10.23 Minutes Standard Deviation 28.891	25.12 Minutes Standard Deviation 29.495	23.79 Minutes Standard Deviation 31.175	5.41 Minutes Standard Deviation 22.381
Change From Baseline in Rapid Eye Movement (REM) Duration on Day 1 and 13 Day 13	5.70 Minutes Standard Deviation 29.875	6.40 Minutes Standard Deviation 25.188	17.42 Minutes Standard Deviation 28.699	12.91 Minutes Standard Deviation 32.051	5.97 Minutes Standard Deviation 28.811

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure the REM latency. REM latency was defined as the time to first REM from sleep onset to reaching the first epoch of REM sleep.

Outcome measures

Outcome measures
Measure	Placebo n=73 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=70 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=70 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=72 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Rapid Eye Movement (REM) Latency on Day 1 and 13 Day 1	-26.60 Minute Standard Deviation 82.487	-38.06 Minute Standard Deviation 79.396	-85.61 Minute Standard Deviation 84.380	-88.36 Minute Standard Deviation 76.551	-42.73 Minute Standard Deviation 67.024
Change From Baseline in Rapid Eye Movement (REM) Latency on Day 1 and 13 Day 13	-26.41 Minute Standard Deviation 87.903	-32.11 Minute Standard Deviation 86.623	-83.89 Minute Standard Deviation 83.313	-73.40 Minute Standard Deviation 81.747	-31.59 Minute Standard Deviation 64.953

SECONDARY outcome

Timeframe: Day 1 and 13

PSG was used to measure the sleep-onset REM in participants. REM sleep periods within 15 minutes from sleep onset were measured.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Percentage of Participants With Sleep-Onset Rapid Eye Movement on Day 1 and 13 Day 1	1.3 percentage of participants	4.2 percentage of participants	9.6 percentage of participants	14.1 percentage of participants	0 percentage of participants
Percentage of Participants With Sleep-Onset Rapid Eye Movement on Day 1 and 13 Day 13	1.4 percentage of participants	2.9 percentage of participants	4.1 percentage of participants	8.7 percentage of participants	2.9 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure the number of sleep cycles.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Number of Sleep Cycles on Day 1 and 13 Day 1	0.43 sleep cycles Standard Deviation 1.138	0.40 sleep cycles Standard Deviation 1.006	0.97 sleep cycles Standard Deviation 1.049	0.75 sleep cycles Standard Deviation 1.155	0.62 sleep cycles Standard Deviation 0.941
Change From Baseline in Number of Sleep Cycles on Day 1 and 13 Day 13	0.20 sleep cycles Standard Deviation 1.222	0.41 sleep cycles Standard Deviation 1.062	0.77 sleep cycles Standard Deviation 1.182	0.45 sleep cycles Standard Deviation 1.219	0.32 sleep cycles Standard Deviation 0.955

SECONDARY outcome

Timeframe: Baseline, Day 1 and 13

PSG was used to measure total time spent in non-rapid eye movement sleep stages N1, N2 and N3. Total time spent was sum of N1, N2 and N3. Positive changes in NREM duration indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=71 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Total Time Spent in Non-Rapid Eye Movement Sleep on Day 1 and 13 Day 1	27.87 Minutes Standard Deviation 68.202	37.62 Minutes Standard Deviation 49.817	56.08 Minutes Standard Deviation 45.218	57.29 Minutes Standard Deviation 54.245	58.47 Minutes Standard Deviation 52.803
Change From Baseline in Total Time Spent in Non-Rapid Eye Movement Sleep on Day 1 and 13 Day 13	32.74 Minutes Standard Deviation 61.726	39.33 Minutes Standard Deviation 61.524	47.41 Minutes Standard Deviation 59.791	51.37 Minutes Standard Deviation 59.310	33.28 Minutes Standard Deviation 62.466

SECONDARY outcome

Timeframe: Baseline, Days 2 and 14

Population: FAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure and 'n' (number analyzed) signifies number of participants who were evaluable at specified time points.

CSD-M is a standardized participant diary based on expert consensus and qualitative participant input to retrieve patient reported subjective sleep parameters related to prior night's sleep. CSD-M parameters analyzed includes: sSOL, sTST, sWASO. Negative change in sSOL, sWASO indicate improvement. Positive change in sTST indicates improvement.

Outcome measures

Outcome measures
Measure	Placebo n=71 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=66 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=68 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO), Subjective Total Sleep Time (sTST) sWASO : Day 14	-5.60 Minutes Standard Deviation 55.955	-18.25 Minutes Standard Deviation 56.719	-25.20 Minutes Standard Deviation 58.872	-20.16 Minutes Standard Deviation 65.568	-17.56 Minutes Standard Deviation 51.007
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO), Subjective Total Sleep Time (sTST) sTST: Day 2	-12.64 Minutes Standard Deviation 96.051	4.90 Minutes Standard Deviation 92.105	29.25 Minutes Standard Deviation 67.934	34.50 Minutes Standard Deviation 76.904	37.07 Minutes Standard Deviation 71.297
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO), Subjective Total Sleep Time (sTST) sSOL: Day 2	15.20 Minutes Standard Deviation 61.761	-3.99 Minutes Standard Deviation 46.858	-16.49 Minutes Standard Deviation 42.699	-27.60 Minutes Standard Deviation 34.456	-24.98 Minutes Standard Deviation 30.395
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO), Subjective Total Sleep Time (sTST) sSOL: Day 14	10.92 Minutes Standard Deviation 68.201	-8.81 Minutes Standard Deviation 45.936	-31.33 Minutes Standard Deviation 36.888	-33.93 Minutes Standard Deviation 37.274	-14.53 Minutes Standard Deviation 53.705
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO), Subjective Total Sleep Time (sTST) sWASO: Day 2	0.81 Minutes Standard Deviation 75.475	-5.47 Minutes Standard Deviation 61.067	-18.54 Minutes Standard Deviation 51.301	-13.28 Minutes Standard Deviation 48.225	-15.99 Minutes Standard Deviation 84.549
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO), Subjective Total Sleep Time (sTST) sTST: Day 14	3.30 Minutes Standard Deviation 89.019	29.34 Minutes Standard Deviation 83.772	36.79 Minutes Standard Deviation 88.379	45.35 Minutes Standard Deviation 81.983	27.68 Minutes Standard Deviation 90.387

SECONDARY outcome

Timeframe: Baseline, Days 2 and 14

The CSD-M is a standardized participant diary based on expert consensus and qualitative participant input to retrieve patient reported subjective sleep parameters related to the prior night's sleep. Sleep quality and how well rested participants felt at awaking are rated on a 5-point Likert scale ranging from 1 (very poor) to 5 (very good). Higher ratings indicate better sleep quality (sQUAL) and more refreshing/restorative quality of sleep (sFRESH). CSD-M parameters analyzed includes: sFRESH and sQUAL. Positive change in sFRESH and sQUAL indicates improvement.

Outcome measures

Outcome measures
Measure	Placebo n=71 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=66 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=68 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Subjective Refreshed Feeling on Waking (sFRESH) and Subjective Quality of Sleep (sQUAL) sFRESH: Day 2	0.07 Units on a Scale Standard Deviation 0.930	0.14 Units on a Scale Standard Deviation 0.865	0.34 Units on a Scale Standard Deviation 0.852	0.58 Units on a Scale Standard Deviation 1.050	0.41 Units on a Scale Standard Deviation 0.876
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Subjective Refreshed Feeling on Waking (sFRESH) and Subjective Quality of Sleep (sQUAL) sFRESH: Day 14	0.26 Units on a Scale Standard Deviation 0.826	0.39 Units on a Scale Standard Deviation 1.081	0.51 Units on a Scale Standard Deviation 1.005	0.59 Units on a Scale Standard Deviation 1.018	0.41 Units on a Scale Standard Deviation 1.051
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Subjective Refreshed Feeling on Waking (sFRESH) and Subjective Quality of Sleep (sQUAL) sQUAL: Day 2	0.11 Units on a Scale Standard Deviation 0.995	0.14 Units on a Scale Standard Deviation 1.054	0.49 Units on a Scale Standard Deviation 0.896	0.49 Units on a Scale Standard Deviation 1.091	0.66 Units on a Scale Standard Deviation 0.818
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Subjective Refreshed Feeling on Waking (sFRESH) and Subjective Quality of Sleep (sQUAL) sQUAL: Day 14	0.26 Units on a Scale Standard Deviation 1.024	0.43 Units on a Scale Standard Deviation 1.172	0.79 Units on a Scale Standard Deviation 1.189	0.67 Units on a Scale Standard Deviation 1.159	0.52 Units on a Scale Standard Deviation 1.084

SECONDARY outcome

Timeframe: Baseline, Days 2 and 14

CSD-M is a standardized participant diary based on expert consensus and qualitative participant input to retrieve patient reported subjective sleep parameters related to the prior night's sleep. CSD-M parameters analyzed include: s-nNAW. Negative change in s-nNAW indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=71 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=66 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=68 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Number of Nighttime Awakenings (s-nNAW) Day 14	0.10 awakenings Standard Deviation 1.234	0.04 awakenings Standard Deviation 1.580	0.05 awakenings Standard Deviation 1.320	-0.02 awakenings Standard Deviation 1.175	-0.22 awakenings Standard Deviation 1.376
Change From Baseline in Subjective Sleep Parameters Using Consensus Sleep Diary - Morning Administration (CSD-M) on Days 2 and 14: Number of Nighttime Awakenings (s-nNAW) Day 2	0.64 awakenings Standard Deviation 2.197	0.21 awakenings Standard Deviation 1.465	0.49 awakenings Standard Deviation 1.465	0.27 awakenings Standard Deviation 1.418	0.38 awakenings Standard Deviation 6.076

SECONDARY outcome

Timeframe: Baseline, Days 8 and 14

PROMIS Sleep Disturbance (PROMIS-SD) Short Form subscale consists of a static 8-item questionnaire. Using a recall period of the past 7 days, it assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Each question has 5 response options ranging in value from 1 to 5. To find the total raw score for a short form with all questions answered, sum the values of the response to each question and a total score ranges from 8 to 40. Lower scores indicate less sleep disturbance. Negative changes in scores indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=63 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=60 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=66 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=63 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=66 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Sleep Disturbance as Measured by Patient Reported Outcome Measurement Information System - Sleep Disturbance (PROMIS-SD) Total Score on Days 8 and 14 Day 8	-4.9 Unit on a Scale Standard Deviation 6.81	-9.0 Unit on a Scale Standard Deviation 7.13	-9.2 Unit on a Scale Standard Deviation 7.17	-9.6 Unit on a Scale Standard Deviation 8.16	-8.3 Unit on a Scale Standard Deviation 7.31
Change From Baseline in Sleep Disturbance as Measured by Patient Reported Outcome Measurement Information System - Sleep Disturbance (PROMIS-SD) Total Score on Days 8 and 14 Day 14	-5.7 Unit on a Scale Standard Deviation 7.75	-10.8 Unit on a Scale Standard Deviation 7.64	-10.3 Unit on a Scale Standard Deviation 7.39	-9.5 Unit on a Scale Standard Deviation 7.93	-10.1 Unit on a Scale Standard Deviation 8.06

SECONDARY outcome

Timeframe: Baseline, Days 8 and 14

PROMIS-Sleep Related Impairment (PROMIS-SRI) scale consists of 8 items to evaluate daytime consequences of functioning 5-point Likert scale ranging from 1 to 5. PROMIS-SRI measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and perceived functional impairments during wakefulness associated with sleep problems or impaired alertness. Each question has five response options ranging in value from 1 to 5. To find total raw score (which range from 8 to 40) with all questions answered, sum values of response to each question. Higher score indicates greater sleep impairment.

Outcome measures

Outcome measures
Measure	Placebo n=61 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=59 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=63 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=62 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=65 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Impairment as Measured by Patient Reported Outcome Measurement Information System - Sleep Related Impairment (PROMIS-SRI) Total Score on Days 8 and 14 Day 8	-4.0 Units on a Scale Standard Deviation 6.56	-7.0 Units on a Scale Standard Deviation 6.15	-5.5 Units on a Scale Standard Deviation 6.55	-8.8 Units on a Scale Standard Deviation 7.09	-4.9 Units on a Scale Standard Deviation 6.98
Change From Baseline in Impairment as Measured by Patient Reported Outcome Measurement Information System - Sleep Related Impairment (PROMIS-SRI) Total Score on Days 8 and 14 Day 14	-5.2 Units on a Scale Standard Deviation 6.88	-9.1 Units on a Scale Standard Deviation 6.53	-6.3 Units on a Scale Standard Deviation 6.94	-7.8 Units on a Scale Standard Deviation 6.98	-7.4 Units on a Scale Standard Deviation 6.35

SECONDARY outcome

Timeframe: Baseline and Day 14

The PGI-S is a self-reported scale to measure severity of illness using a 6-point scale ranging from 1 to 6, (1=no insomnia, 2=very mild, 3=mild, 4=moderate, 5=severe, 6=very severe). Considering all aspects of insomnia, participants rated their severity on the PGI-S scale. Negative changes in scores indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=59 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=59 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=65 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=62 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=65 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Participant's Assessment of Insomnia Severity Using the Patient Global Impression - Severity (PGI-S) Scale Score on Day 14	0.00 Unit on a Scale Full Range -5.0 • Interval -5.0 to 2.0	-1.00 Unit on a Scale Full Range -4.0 • Interval -4.0 to 2.0	-1.00 Unit on a Scale Full Range -4.0 • Interval -4.0 to 1.0	-1.00 Unit on a Scale Full Range -5.0 • Interval -5.0 to 1.0	-1.00 Unit on a Scale Full Range -4.0 • Interval -4.0 to 1.0

SECONDARY outcome

Timeframe: Baseline and Day 14

PGI-I is a self-reported scale to measure improvement in illness using a 7-point scale ranging from 1 to 7, (1=very much improved, 2=much improved, 3=improved \[just enough to make a difference\], 4=no change, 5=worse \[just enough to make a difference\], 6=much worse, 7=very much worse). Negative changes in scores indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=60 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=62 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=69 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=65 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=67 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Participant's Assessment of Improvement in Insomnia Using the Patient Global Impression - Improvement (PGI-I) Scale Score on Day 14	3.00 Units on a Scale Full Range 0.0 • Interval 0.0 to 5.0	2.00 Units on a Scale Full Range 0.0 • Interval 0.0 to 5.0	2.00 Units on a Scale Full Range 0.0 • Interval 0.0 to 4.0	2.00 Units on a Scale Full Range 0.0 • Interval 0.0 to 4.0	2.00 Units on a Scale Full Range 0.0 • Interval 0.0 to 5.0

SECONDARY outcome

Timeframe: Day 14

Population: FAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number participants evaluable for this outcome measure. Participants with missing values at a given time point were excluded from frequency calculation for that time point.

Percentage of participants who achieved at least 50% reduction from baseline in ISI total score (responders) were reported. It is a 7-item questionnaire assessing nature, severity, impact of insomnia. Dimensions evaluated: severity of sleep onset, sleep maintenance, early morning awakening problems; sleep dissatisfaction; interference of sleep problem with daytime functioning; noticeability of sleep problems; distress caused by sleep difficulties. 5-point Likert scale (0-4) was used to rate each item, Scores are summed for a total score which ranges from 0-28. Negative changes in scores indicate improvement. ISI total score is the sum of all item scores. Total score interpreted insomnia as follows: absence (0-7); sub-threshold (8-14); moderate (15-21); severe (22-28).

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=69 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=70 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Percentage of Participants Who Achieved Response Based on Insomnia Severity Index (ISI) Total Score on Day 14 - Observed Case	23.2 percentage of participants	42.0 percentage of participants	31.5 percentage of participants	34.8 percentage of participants	42.9 percentage of participants

SECONDARY outcome

Timeframe: Day 14

Population: FAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Participants with missing values at a given time point are excluded from the frequency calculation for that time point.

Percentage of participants with remission of insomnia symptom defined as, total score of \<= 10 on ISI scale. ISI is 7-item questionnaire assessing nature, severity, impact of insomnia. Dimensions evaluated are: severity of sleep onset, sleep maintenance, early morning awakening problems; sleep dissatisfaction; interference of sleep problem with daytime functioning; noticeability of sleep problems by others; distress caused by sleep difficulties. 5-point Likert scale (0-4) is used to rate each item. ISI total score is the sum of all item scores. ISI total score is the sum of all item scores. Scores are summed for a total score which ranges from 0-28 and interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); severe insomnia (22-28).

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=69 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=70 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Percentage of Participants Who Achieved Remission Based on Insomnia Severity Index (ISI) Total Score on Day 14 - Observed Case	24.6 percentage of participants	43.5 percentage of participants	37.0 percentage of participants	39.1 percentage of participants	50.0 percentage of participants

SECONDARY outcome

Timeframe: Baseline and Day 14

The CGI-S is a 7-point scale to measure severity of illness (1=normal \[not at all ill\], 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants). Higher score indicates more severity. Negative changes in scores indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=69 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=70 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Clinician's Assessment of Insomnia Severity Using the Clinical Global Impression - Severity (CGI-S) Score on Day 14	0.0 Units on a scale Interval -5.0 to 1.0	-1.0 Units on a scale Interval -5.0 to 3.0	-1.0 Units on a scale Interval -5.0 to 2.0	-1.0 Units on a scale Interval -5.0 to 1.0	-1.0 Units on a scale Interval -5.0 to 0.0

SECONDARY outcome

Timeframe: Baseline and Day 14

The CGI-I is a 7-point scale to measure improvement in illness using a 7-point scale ranging from 1 to 7 (1=very much improved, 2=much improved, 3=minimally improved, 4=no change from baseline, 5=minimally worse, 6=much worse, 7=very much worse). Higher score indicates more severity. Negative changes in scores indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=69 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=70 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Clinician's Assessment of Insomnia Improvement Using Clinical Global Impression-Improvement (CGI-I) Score on Day 14	3.0 Units on a Scale Interval 1.0 to 5.0	3.0 Units on a Scale Interval 1.0 to 5.0	3.0 Units on a Scale Interval 1.0 to 4.0	3.0 Units on a Scale Interval 1.0 to 5.0	2.0 Units on a Scale Interval 1.0 to 5.0

SECONDARY outcome

Timeframe: Up to Day 17

Population: Safety analysis set (SAS) included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Treatment-emergent adverse events are adverse events with an onset date occurring at or after the initial administration of study drug through the Day 17 telephone contact date, or the day of last dose plus 3 days for participants without the Day 17 telephone contact date.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=72 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability	37 Participants	29 Participants	23 Participants	21 Participants	31 Participants

SECONDARY outcome

Timeframe: Up to Day 17

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

Treatment-emergent serious adverse events are serious adverse events with an onset date occurring at or after the initial administration of study drug through the Day 17 telephone contact date, or the day of last dose plus 3 days for participants without the Day 17 telephone contact date. Events of special interest included: Cataplexy; Sleep paralysis; Complex sleep-related behaviors such as confusional arousals, somnambulism (sleep walking), sleep terrors, bruxism (teeth grinding), sleep sex, sleep related eating disorder, sleep behavior disorder, and catathrenia (REM-associated end-inspiratory apnea/breath holding); Abnormal dreams; Falls.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=72 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Number of Participants With Treatment-Emergent Serious Adverse Events and Events of Special Interest Treatment-emergent Serious AE	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Treatment-Emergent Serious Adverse Events and Events of Special Interest Events of Special Interest	2 Participants	1 Participants	2 Participants	1 Participants	4 Participants

SECONDARY outcome

Timeframe: Up to Day 15

Clinically significant vital signs (pulse, supine and standing blood pressure (systolic and diastolic), and oral, temperature) and physical abnormalities (body weight) were reported. Abnormally low parameters included pulse (bpm)- decrease value from baseline greater than or equal to (\>=) 15 to \<=50; Systolic BP (mmHg \[Millimeter of mercury\])- decrease value from baseline \>=20 to \<=90; Diastolic BP- decrease value from baseline \>=15 to \<=50; weight (Kilogram\[Kg\])- decrease from baseline \>=7%; Body temperature (Celsius \[C\])- \<35.5. Abnormally high parameters included pulse- increase value from baseline \>=15 to \>=100; Systolic BP(mmHg)- increase from baseline of \>=20 to \>=180; Diastolic BP- increase value from baseline \>=15 to \>=105; weight(Kg)- increase from baseline of \>=7%; body temperature (C)- \>37.5.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=72 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Supine Pulse Rate: Abnormally low	2 Participants	2 Participants	2 Participants	3 Participants	0 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Supine Pulse Rate: Abnormally high	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Standing Pulse Rate: Abnormally low	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Standing Pulse Rate: Abnormally high	8 Participants	7 Participants	3 Participants	6 Participants	11 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Supine Systolic BP: Abnormally low	3 Participants	0 Participants	3 Participants	2 Participants	2 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Supine Systolic BP: Abnormally high	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Standing Systolic BP: Abnormally low	2 Participants	1 Participants	1 Participants	3 Participants	5 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Standing Systolic BP: Abnormally high	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Supine Diastolic BP: Abnormally low	2 Participants	0 Participants	0 Participants	0 Participants	4 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Supine Diastolic BP: Abnormally high	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Standing Diastolic BP: Abnormally low	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Standing Diastolic BP: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Temperature: Abnormally low	2 Participants	3 Participants	0 Participants	3 Participants	2 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Temperature: Abnormally high	1 Participants	0 Participants	0 Participants	2 Participants	1 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Weight: Abnormally low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Vital Signs and Physical Abnormalities Weight: Abnormally high	2 Participants	0 Participants	0 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 14

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies number of participants who were evaluable for specified categories.

Twelve-lead ECGs were recorded in a supine position and different ECG intervals (Respiratory rate \[RR\], PR, time for ventricular depolarization \[QRS\], and total time from ventricular depolarization to complete repolarization \[QT\]) and heart rate was measured. This included heart rate:\<=50 beats per minute (bpm) and \>=100 bpm; PR interval \<=120 millisecond (msec) and \>=200 msec; QRS interval: \<=60 msec and \>=120 msec; QT interval:\<=200 msec and \>=500 msec.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=70 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=71 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=68 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=71 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities Heart rate: <=50 bpm	10 Participants	7 Participants	5 Participants	6 Participants	6 Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities Heart rate:>=100 bpm	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities PR interval: <=120 msec	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities PR interval: >=200 msec	4 Participants	4 Participants	4 Participants	2 Participants	7 Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities QRS interval: <=60 msec	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities QRS interval: >=120 msec	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities QT interval: <=200 msec	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities QT interval: >=500 msec	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 15

Population: Analysis population was SAS. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Here,'n' (number analyzed) signifies number of participants who were evaluable for specified categories. 1 participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922.This participant was summarized under the 5 mg dose group for safety analyses.

Number of participants with clinically significant laboratory abnormalities were reported. Blood samples for serum chemistry (albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bicarbonate, calcium, chloride, creatine Kinase, gamma glutamyl transferase, lactate dehydrogenase, phosphate, potassium, sodium), and urinalysis (bilirubin, protein) were collected for clinical laboratory testing.

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=70 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=71 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=68 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=71 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Number of Participants With Clinically Significant Laboratory Abnormalities Alanine Aminotransferase: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Albumin: Abnormally low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Albumin: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Alkaline Phosphatase: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Aspartate Aminotransferase: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Bicarbonate: Abnormally low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Bicarbonate: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Bilirubin: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Calcium: Abnormally low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Calcium: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Chloride: Abnormally low	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Chloride: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Creatine Kinase: Abnormally high	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Creatinine: Abnormally high	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Direct Bilirubin: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Gamma Glutamyl Transferase: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Lactate Dehydrogenase: Abnormally high	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Phosphate: Abnormally low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Phosphate: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Potassium: Abnormally low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Potassium: Abnormally high	0 Participants	0 Participants	3 Participants	1 Participants	2 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Protein: Abnormally low	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Sodium: Abnormally low	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinically Significant Laboratory Abnormalities Sodium: Abnormally high	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 14

Population: SAS included all participants who were randomly assigned to drug and received at least 1 dose of drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. 1 participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922 and was summarized under 5 mg dose group for safety analyses.

C-SSRS is a questionnaire designed to solicit occurrence, severity, frequency of suicidal ideation/behaviors using following scores: Suicidal Ideation-1:Wish to be Dead; 2:Non-specific Active Suicidal Thoughts; 3:Active Suicidal Ideation with Any Methods without Intent to Act; 4:Active Suicidal Ideation with Some Intent to Act; 5:Active Suicidal Ideation with Specific Plan/Intent; Suicidal Behavior-6:Preparatory Acts; 7:Aborted Attempt; 8:Interrupted Attempt; 9:Actual Attempt; 10:Completed Suicide. If no events qualify for score of 1-10, score 0 indicate "no event that can be assessed on basis of C-SSRS". Higher scores= greater severity.

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=70 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=72 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=69 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=70 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 0: No Event	69 Participants	70 Participants	72 Participants	69 Participants	70 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 10: Completed Suicide	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 1: Wish to be Dead	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 2: Non-Specific Active Suicidal Thoughts	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 3: Suicidal Ideation Without Plan and Intent	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 4: Suicidal Ideation Intent to Act Without Plan	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 5: Suicidal Ideation With Plan and Intent	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 6: Preparatory Acts or Behavior	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 7: Aborted Attempt	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 8: Interrupted Attempt	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Suicidal Ideation and Behavior as Determined by Columbia Suicide Severity Rating Scale (C-SSRS) Score Score 9: Actual Attempt	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline, Days 2 and 14

Population: Analysis population was SAS. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies number of participants who were evaluable at specified time points. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

The KSS is a patient reported assessment of level of drowsiness at the time of scale administration. This scale is focused mainly on the propensity to fall asleep and has a high validity in measuring sleepiness. It consists of a single item assessed on 9-point Likert scale with response options from: 1=very alert to 9=very sleepy (fighting sleep). Negative changes indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=66 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=62 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=65 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=59 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=67 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Karolinska Sleepiness Scale (KSS) Total Score on Days 2 and 14 Day 2	0.3 Units on a Scale Standard Deviation 1.75	-0.4 Units on a Scale Standard Deviation 1.86	-0.2 Units on a Scale Standard Deviation 1.42	-0.5 Units on a Scale Standard Deviation 1.86	-0.4 Units on a Scale Standard Deviation 1.68
Change From Baseline in Karolinska Sleepiness Scale (KSS) Total Score on Days 2 and 14 Day 14	0.1 Units on a Scale Standard Deviation 1.82	-0.8 Units on a Scale Standard Deviation 2.15	-0.6 Units on a Scale Standard Deviation 1.72	-0.7 Units on a Scale Standard Deviation 1.90	-0.7 Units on a Scale Standard Deviation 2.01

SECONDARY outcome

Timeframe: Day 14 (morning)

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. One participant who was randomized to JNJ-42847922 10mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. Body sway was measured using an ataxiameter. Participants were instructed to wear a pair of thin socks for each session. Before starting a measurement, participants were asked to stand still and comfortable, with their feet approximately 10 centimeters (cm) apart and their hands in a relaxed position alongside the body and eyes closed. The total period of body sway measurement was 2 minutes.

Outcome measures

Outcome measures
Measure	Placebo n=66 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=66 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=69 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=67 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Postural Stability Measured by Ataxiameter	-0.06 1/3 Degree Angle of Arc Standard Deviation 17.15	3.14 1/3 Degree Angle of Arc Standard Deviation 16.14	-0.87 1/3 Degree Angle of Arc Standard Deviation 15.62	-0.25 1/3 Degree Angle of Arc Standard Deviation 14.71	1.65 1/3 Degree Angle of Arc Standard Deviation 14.11

SECONDARY outcome

Timeframe: Baseline and Day 14 (Morning)

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

Power of Attention is a combination of the speed scores from the three tests of attention, and is established to reflect the ability to focus attention and to process information. Power of Attention was calculated from the sum of the reaction time measured from the attentional tasks (Simple Reaction Time, Choice Reaction Time and Digit Vigilance Speed). Score ranges from 450 milliseconds - 61500 milliseconds. A low score reflects a fast reaction time and a high intensity of concentration.

Outcome measures

Outcome measures
Measure	Placebo n=67 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=66 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=67 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Power of Attention as Measured by a Computerized Battery of Cognitive Tests on Day 14 (Morning)	35.88 milliseconds (ms) Standard Deviation 125.43	48.59 milliseconds (ms) Standard Deviation 137.75	67.09 milliseconds (ms) Standard Deviation 257.67	37.07 milliseconds (ms) Standard Deviation 124.23	35.38 milliseconds (ms) Standard Deviation 189.99

SECONDARY outcome

Timeframe: Baseline and Day 14 (Morning)

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this endpoint. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

Continuity of attention is a measure of sustained attention, combining (summed) accuracy and error measures from the choice reaction time and digit vigilance tasks. The number of correct responses (out of 50) for choice reaction time was added to the total number of targets correctly identified (out of 45) digit vigilance minus the number of false alarms (total score of -45 to 95). A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline.

Outcome measures

Outcome measures
Measure	Placebo n=67 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=66 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=67 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Continuity of Attention as Measured by a Computerized Battery of Cognitive Tests on Day 14 (Morning)	0.36 units on a scale Standard Deviation 5.31	-0.20 units on a scale Standard Deviation 3.16	-1.37 units on a scale Standard Deviation 6.35	0.10 units on a scale Standard Deviation 5.05	-0.39 units on a scale Standard Deviation 5.14

SECONDARY outcome

Timeframe: Baseline and Day 14 (Morning)

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

Quality of working memory is a combination of the scores from Spatial Working Memory and Numeric Working Memory tasks, and is established to reflect the ability to temporarily hold numeric and spatial information in memory. Sum of Spatial and Numeric Working Memory sensitivity indices (SI) (accuracy) was used to calculate the quality of working memory. The quality of working memory score was calculated from formulae that combined the accuracy scores for the original as well as the new (distractor) stimuli. The range for both the numeric working memory and spatial working memory tasks SI are -1 to 1. Smaller scores reflect poorer ability (poorer quality of working memory),larger scores reflect better ability (better quality of working memory). Total score is the sum of Spatial Working Memory and Numeric Working Memory (ranges from -2 to 2). Smaller scores reflect poorer ability (poorer quality of working memory), larger scores reflect better ability (better quality of working memory.

Outcome measures

Outcome measures
Measure	Placebo n=67 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=65 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=67 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Quality of Working Memory as Measured by a Computerized Battery of Cognitive Tests on Day 14 (Morning)	0.00 Units on scale Standard Deviation 0.35	-0.03 Units on scale Standard Deviation 0.28	-0.02 Units on scale Standard Deviation 0.41	-0.04 Units on scale Standard Deviation 0.29	0.05 Units on scale Standard Deviation 0.28

SECONDARY outcome

Timeframe: Baseline and Day 14 (Morning)

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant is summarized under the 5 mg dose group. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure.

Quality of episodic secondary memory is calculated from the sum of 4 tests: Immediate and delayed word recall, and word and picture recognition, and ranges from -200 to 400. A high score reflects a good ability to store, hold and retrieve information of an episodic nature (that is an event or a name) and a negative change from baseline reflects impairment compared to baseline.

Outcome measures

Outcome measures
Measure	Placebo n=66 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=65 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=66 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=67 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Quality of Episodic Secondary Memory as Measured by a Computerized Battery of Cognitive Tests on Day 14 (Morning)	-22.84 units on scale Standard Deviation 53.73	-23.15 units on scale Standard Deviation 46.02	-33.58 units on scale Standard Deviation 48.82	-25.45 units on scale Standard Deviation 56.37	-37.96 units on scale Standard Deviation 55.94

SECONDARY outcome

Timeframe: Baseline and Day 14 (Morning)

The sum of the speed measures from the two working memory tasks (Spatial and Numeric) and the two recognition tasks (Word and Picture). Speed of Memory combines reaction times from Spatial Working Memory (range:150 to 30000 millisecond \[ms\]), Numeric Working Memory (150 to 30000 ms), Word Recognition (250 to 30000 ms) and Picture recognition (250 to 30000 ms) tasks. The total reaction time (sum of above 4 reaction times) measures memory retrieval speed which ranges from 800 to 120000 ms. Slower reaction time reflect poorer ability and faster reaction time reflect better ability.

Outcome measures

Outcome measures
Measure	Placebo n=67 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=65 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=68 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=67 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change From Baseline in Speed of Memory as Measured by a Computerized Battery of Cognitive Tests on Day 14 (Morning)	-104.75 millisecond Standard Deviation 787.74	258.38 millisecond Standard Deviation 719.56	7.57 millisecond Standard Deviation 806.27	-65.67 millisecond Standard Deviation 761.77	-83.70 millisecond Standard Deviation 1060.38

SECONDARY outcome

Timeframe: Day 14 to Day 17

CSD-M is a standardized participant diary based on expert consensus and qualitative participant input to retrieve patient reported subjective sleep parameters related to prior night's sleep. Negative change in sSOL, sWASO indicate improvement and positive change in Subjective Total Sleep Time (sTST) indicates improvement.

Outcome measures

Outcome measures
Measure	Placebo n=63 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=58 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=57 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=56 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=58 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change in Subjective Sleep Parameters From Day 14 as Compared to Day 17 as Measured by the Consensus Sleep Diary-Morning Administration (CSD-M):Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO) and sTST sWASO	-12.39 Minutes Standard Deviation 57.711	-0.76 Minutes Standard Deviation 66.663	-2.13 Minutes Standard Deviation 41.505	-10.80 Minutes Standard Deviation 63.672	3.76 Minutes Standard Deviation 58.805
Change in Subjective Sleep Parameters From Day 14 as Compared to Day 17 as Measured by the Consensus Sleep Diary-Morning Administration (CSD-M):Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO) and sTST sSOL	-20.56 Minutes Standard Deviation 74.145	-4.83 Minutes Standard Deviation 43.769	9.67 Minutes Standard Deviation 29.798	15.55 Minutes Standard Deviation 32.327	9.57 Minutes Standard Deviation 72.253
Change in Subjective Sleep Parameters From Day 14 as Compared to Day 17 as Measured by the Consensus Sleep Diary-Morning Administration (CSD-M):Self-Reported Sleep-Onset Latency (sSOL), Subjective Wake After Sleep Onset (sWASO) and sTST sTST	30.95 Minutes Standard Deviation 101.367	13.07 Minutes Standard Deviation 102.093	6.96 Minutes Standard Deviation 96.664	19.71 Minutes Standard Deviation 66.447	-7.95 Minutes Standard Deviation 102.183

SECONDARY outcome

Timeframe: Day 14 to Day 17

CSD-M is a standardized subject diary based on expert consensus and qualitative subject input to retrieve patient reported subjective sleep parameters related to the prior night's sleep. Sleep quality (sQUAL) and how well rested subjects felt at awaking are rated on a 5-point Likert scale ranging from 1 (very poor) to 5 (very good). Higher ratings indicate better sleep quality and more refreshing/restorative quality of sleep (sFRESH). CSD-M parameters analyzed includes: sFRESH and sQUAL. Positive change in sFRESH and sQUAL indicates improvement.

Outcome measures

Outcome measures
Measure	Placebo n=63 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=58 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=57 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=56 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=58 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change in Subjective Sleep Parameters From Day 14 as Compared to Day 17 Using Consensus Sleep Diary-Morning Administration: Subjective Refreshed Feeling on Waking (sFRESH) and Subjective Quality of Sleep (sQUAL) sFRESH	0.13 Units on a Scale Standard Deviation 1.085 • Interval 1.085 to	0.17 Units on a Scale Standard Deviation 1.011 • Interval 1.011 to	0.04 Units on a Scale Standard Deviation 1.017 • Interval 1.017 to	0.11 Units on a Scale Standard Deviation 1.073 • Interval 1.073 to	-0.03 Units on a Scale Standard Deviation 0.898 • Interval 0.898 to
Change in Subjective Sleep Parameters From Day 14 as Compared to Day 17 Using Consensus Sleep Diary-Morning Administration: Subjective Refreshed Feeling on Waking (sFRESH) and Subjective Quality of Sleep (sQUAL) sQUAL	0.19 Units on a Scale Standard Deviation 1.242 • Interval 1.242 to	0.24 Units on a Scale Standard Deviation 1.129 • Interval 1.129 to	-0.07 Units on a Scale Standard Deviation 1.083 • Interval 1.083 to	0.02 Units on a Scale Standard Deviation 1.120 • Interval 1.12 to	-0.12 Units on a Scale Standard Deviation 1.010 • Interval 1.01 to

SECONDARY outcome

Timeframe: Day 14 to Day 17

CSD-M is a standardized participant diary based on expert consensus and qualitative participant input to retrieve patient reported subjective sleep parameters related to the prior night's sleep. Higher ratings indicate better sleep quality and more refreshing/restorative quality of sleep. CSD-M parameters analyzed includes: s-nNAW. Negative change in s-nNAW indicate improvement.

Outcome measures

Outcome measures
Measure	Placebo n=63 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=58 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=57 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=56 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=58 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Change in Subjective Sleep Parameters From Day 14 as Compared to Day 17 Using Consensus Sleep Diary-Morning Administration (CSD-M): Number of Nighttime Awakenings (s-nNAW)	0.16 awakenings Standard Deviation 3.525 • Interval 3.525 to	-0.59 awakenings Standard Deviation 2.009 • Interval 2.009 to	-0.35 awakenings Standard Deviation 1.217 • Interval 1.217 to	-0.36 awakenings Standard Deviation 1.052 • Interval 1.052 to	-0.34 awakenings Standard Deviation 1.396 • Interval 1.396 to

SECONDARY outcome

Timeframe: Day 14 to Day 17

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participants analyzed) signifies number of participants evaluable for this outcome measure. 1 participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922 and was summarized under 5 mg dose group for safety analyses.

PWC-20 is a reliable, sensitive instrument having 20-items used to assess potential withdrawal symptoms following cessation of treatment. Items are as follows: Loss of Appetite, Nausea-Vomiting, Diarrhea, Anxiety-Nervousness, Irritability, Dysphoric Mood-Depression, Insomnia, Fatigue, Poor Coordination, Restlessness, Diaphoresis, Tremor, Dizziness, Headaches, Stiffness, Weakness, Increased Acuity Sound Smell Touch (IASST), Paresthesias, Remember, Derealization. Each item score ranges from 0 (not present)-3 (severe), where higher scores = more affected condition. Total score ranges from 0-60, where higher score indicates more affected condition. PWC-20 score was imputed as follows: sum of the non-missing items \* (total number of items) / (number of items non-missing).

Outcome measures

Outcome measures
Measure	Placebo n=69 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=69 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=70 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=68 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=69 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Paresthesias:Symptoms Present and Unchanged	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 IASST: Improved Symptoms	1 Participants	1 Participants	1 Participants	3 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 IASST: Symptoms Present and Unchanged	2 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 IASST: New or Worsened Symptoms	2 Participants	1 Participants	3 Participants	2 Participants	4 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Paresthesias:Improved Symptoms	4 Participants	0 Participants	2 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Paresthesias:No Symptoms	62 Participants	68 Participants	66 Participants	68 Participants	68 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Paresthesias:New or Worsened Symptoms	2 Participants	0 Participants	2 Participants	0 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Weakness:Improved Symptoms	3 Participants	0 Participants	3 Participants	3 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Headaches:No Symptoms	56 Participants	51 Participants	61 Participants	60 Participants	56 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Headaches:Improved Symptoms	9 Participants	12 Participants	4 Participants	7 Participants	3 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Headaches:Symptoms Present and Unchanged	2 Participants	5 Participants	3 Participants	0 Participants	3 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Headaches:New or Worsened Symptoms	2 Participants	1 Participants	2 Participants	1 Participants	7 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Stiffness:No Symptoms	59 Participants	62 Participants	64 Participants	63 Participants	59 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Stiffness:Improved Symptoms	8 Participants	2 Participants	2 Participants	3 Participants	3 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Stiffness:Symptoms Present and Unchanged	1 Participants	2 Participants	2 Participants	0 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Stiffness:New or Worsened Symptoms	1 Participants	3 Participants	2 Participants	2 Participants	6 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Weakness:No Symptoms	61 Participants	69 Participants	65 Participants	65 Participants	65 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Weakness:Symptoms Present and Unchanged	3 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Weakness:New or Worsened Symptoms	2 Participants	0 Participants	1 Participants	0 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 IASST: No Symptoms	64 Participants	66 Participants	66 Participants	63 Participants	62 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Loss of Appetite: No Symptoms	65 Participants	69 Participants	65 Participants	68 Participants	66 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Loss of Appetite: Improved Symptoms	0 Participants	0 Participants	4 Participants	0 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Loss of Appetite: Symptoms Present and Unchanged	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Loss of Appetite: New or Worsened Symptoms	4 Participants	0 Participants	1 Participants	0 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Nausea-Vomiting: No Symptoms	67 Participants	67 Participants	66 Participants	67 Participants	63 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Nausea-Vomiting: Improved Symptoms	0 Participants	1 Participants	3 Participants	0 Participants	5 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Nausea-Vomiting: Symptoms Present and Unchanged	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Nausea-Vomiting: New or Worsened Symptoms	2 Participants	1 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diarrhea: No Symptoms	65 Participants	69 Participants	67 Participants	67 Participants	63 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diarrhea: Improved Symptoms	2 Participants	0 Participants	1 Participants	1 Participants	4 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diarrhea: Symptoms Present and Unchanged	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diarrhea: New or Worsened Symptoms	2 Participants	0 Participants	1 Participants	0 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Anxiety-Nervousness: No Symptoms	64 Participants	68 Participants	64 Participants	62 Participants	62 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Anxiety-Nervousness:Improved Symptoms	2 Participants	1 Participants	3 Participants	3 Participants	5 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Anxiety-Nervousness:Symptoms Present and Unchanged	2 Participants	0 Participants	1 Participants	2 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Anxiety-Nervousness: New or Worsened Symptoms	1 Participants	0 Participants	2 Participants	1 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Irritability: No Symptoms	58 Participants	58 Participants	59 Participants	60 Participants	58 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Irritability:Improved Symptoms	6 Participants	9 Participants	5 Participants	4 Participants	9 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Irritability:Symptoms Present and Unchanged	3 Participants	1 Participants	3 Participants	3 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Irritability:New or Worsened Symptoms	2 Participants	1 Participants	3 Participants	1 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dysphoric Mood: No Symptoms	66 Participants	66 Participants	68 Participants	65 Participants	66 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dysphoric Mood: Improved Symptoms	0 Participants	3 Participants	1 Participants	1 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dysphoric Mood: Symptoms Present and Unchanged	2 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dysphoric Mood: New or Worsened Symptoms	1 Participants	0 Participants	0 Participants	1 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Insomnia: No Symptoms	12 Participants	14 Participants	11 Participants	17 Participants	16 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Insomnia: Improved Symptoms	19 Participants	15 Participants	13 Participants	11 Participants	15 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Insomnia: Symptoms Present and Unchanged	27 Participants	28 Participants	32 Participants	28 Participants	21 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Insomnia: New or Worsened Symptoms	11 Participants	12 Participants	14 Participants	12 Participants	17 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Fatigue: No Symptoms	30 Participants	43 Participants	41 Participants	45 Participants	44 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Fatigue: Improved Symptoms	21 Participants	15 Participants	19 Participants	8 Participants	14 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Fatigue: Symptoms Present and Unchanged	5 Participants	7 Participants	8 Participants	9 Participants	5 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Fatigue: New or Worsened Symptoms	13 Participants	4 Participants	2 Participants	6 Participants	6 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Poor Coordination: No Symptoms	61 Participants	65 Participants	63 Participants	61 Participants	61 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Poor Coordination: Improved Symptoms	6 Participants	3 Participants	7 Participants	5 Participants	5 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Poor Coordination: Symptoms Present and Unchanged	1 Participants	1 Participants	0 Participants	1 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Poor Coordination: New/Worsened Symptoms	1 Participants	0 Participants	0 Participants	1 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Restlessness:No Symptoms	55 Participants	59 Participants	59 Participants	60 Participants	60 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Restlessness:Improved Symptoms	9 Participants	6 Participants	9 Participants	5 Participants	7 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Restlessness:Symptoms Present and Unchanged	3 Participants	2 Participants	1 Participants	1 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Restlessness:New or Worsened Symptoms	2 Participants	2 Participants	1 Participants	2 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diaphoresis:No Symptoms	64 Participants	68 Participants	65 Participants	65 Participants	64 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diaphoresis:Improved Symptoms	3 Participants	1 Participants	2 Participants	2 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diaphoresis:Symptoms Present and Unchanged	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Diaphoresis:New or Worsened Symptoms	2 Participants	0 Participants	3 Participants	1 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Tremor: No Symptoms	66 Participants	68 Participants	69 Participants	68 Participants	67 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Tremor: Improved Symptoms	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Tremor: Symptoms Present and Unchanged	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Tremor: New or Worsened Symptoms	1 Participants	0 Participants	1 Participants	0 Participants	2 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dizziness:No Symptoms	63 Participants	69 Participants	66 Participants	64 Participants	60 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dizziness: Improved Symptoms	3 Participants	0 Participants	2 Participants	3 Participants	7 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dizziness: Symptoms Present and Unchanged	1 Participants	0 Participants	1 Participants	1 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Dizziness:New or Worsened Symptoms	2 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Remember:No Symptoms	50 Participants	60 Participants	56 Participants	56 Participants	53 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Remember:Improved Symptoms	9 Participants	7 Participants	9 Participants	8 Participants	6 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Remember:Symptoms Present and Unchanged	5 Participants	1 Participants	4 Participants	1 Participants	5 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Remember:New or Worsened Symptoms	5 Participants	1 Participants	1 Participants	3 Participants	5 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Derealization:No Symptoms	64 Participants	68 Participants	68 Participants	67 Participants	68 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Derealization:Improved Symptoms	4 Participants	1 Participants	1 Participants	1 Participants	1 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Derealization:Symptoms Present and Unchanged	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Withdrawal Symptoms of JNJ-42847922 as Measured by Physician Withdrawal Checklist (PWC) From Day 14 to Day 17 Derealization:New or Worsened Symptoms	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 17

Population: SAS included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. Here, N (number of participant analyzed) signifies number of participants evaluable for this outcome measure. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

The BWSQ is a 20 symptom self-reported questionnaire to investigate withdrawal symptoms. Total score is the sum of item scores. Total scores can range from 0-40 with higher scores indicating greater severity of symptoms. Participants rated the degree to which they were experiencing each symptom as either "0=No," "1=Yes-moderate" or "2=Yes-severe". The questionnaire had been shown to be reliable and to have acceptable construct validity in assessing withdrawal symptoms.

Outcome measures

Outcome measures
Measure	Placebo n=58 Participants Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=54 Participants Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=56 Participants Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=51 Participants Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=55 Participants Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) Total Score for Self-Assessment of Withdrawal Symptoms on Day 17	1.5 Units on a Scale Standard Deviation 2.58	1.2 Units on a Scale Standard Deviation 1.90	2.0 Units on a Scale Standard Deviation 3.44	1.5 Units on a Scale Standard Deviation 2.93	2.0 Units on a Scale Standard Deviation 3.10

Adverse Events

Placebo

Serious events: 0 serious events

Other events: 22 other events

Deaths: 0 deaths

JNJ-42847922 5 mg

Serious events: 0 serious events

Other events: 16 other events

Deaths: 0 deaths

JNJ-42847922 10 mg

Serious events: 0 serious events

Other events: 10 other events

Deaths: 0 deaths

JNJ-42847922 20 mg

Serious events: 1 serious events

Other events: 13 other events

Deaths: 0 deaths

Zolpidem

Serious events: 1 serious events

Other events: 21 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo n=75 participants at risk Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=72 participants at risk Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 participants at risk Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 participants at risk Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 participants at risk Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Nervous system disorders Cerebral Haemorrhage	0.00% 0/75 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/72 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/73 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/71 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/73 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Nervous system disorders Cognitive Disorder	0.00% 0/75 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/72 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/73 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/71 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/73 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

Other adverse events

Other adverse events
Measure	Placebo n=75 participants at risk Participants received matching placebo as 2 oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 5 mg n=72 participants at risk Participants received JNJ-42847922 5 milligrams (mg) dose as two 2.5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 10 mg n=73 participants at risk Participants received JNJ-42847922 10 mg as one 10 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	JNJ-42847922 20 mg n=71 participants at risk Participants received JNJ-42847922 20 mg as one 20 mg oral capsule and one placebo capsule for 14 consecutive nights from Day 1 to Day 14.	Zolpidem n=73 participants at risk Participants received Zolpidem 5 mg as one 5 mg capsule plus one placebo capsule or 10 mg Zolpidem as two 5 mg oral capsules for 14 consecutive nights from Day 1 to Day 14.
Nervous system disorders Somnolence	1.3% 1/75 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/72 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/73 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.6% 4/71 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.5% 4/73 • Number of events 5 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Gastrointestinal disorders Diarrhoea	4.0% 3/75 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/72 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/73 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/71 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.5% 4/73 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Gastrointestinal disorders Nausea	2.7% 2/75 • Number of events 2 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/72 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	2.7% 2/73 • Number of events 2 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/71 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	6.8% 5/73 • Number of events 5 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
General disorders Fatigue	10.7% 8/75 • Number of events 8 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.6% 4/72 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	4.1% 3/73 • Number of events 3 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	2.8% 2/71 • Number of events 2 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	2.7% 2/73 • Number of events 2 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Infections and infestations Nasopharyngitis	1.3% 1/75 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.6% 4/72 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/73 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/71 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/73 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Infections and infestations Urinary Tract Infection	5.3% 4/75 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/72 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/73 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/71 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/73 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Musculoskeletal and connective tissue disorders Myalgia	4.0% 3/75 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/72 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/73 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/71 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.5% 4/73 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Nervous system disorders Disturbance in Attention	5.3% 4/75 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	2.8% 2/72 • Number of events 2 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/73 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/71 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.5% 4/73 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Nervous system disorders Dizziness	1.3% 1/75 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/72 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/73 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/71 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	6.8% 5/73 • Number of events 7 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Nervous system disorders Headache	10.7% 8/75 • Number of events 8 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	9.7% 7/72 • Number of events 8 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	5.5% 4/73 • Number of events 6 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	8.5% 6/71 • Number of events 8 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	11.0% 8/73 • Number of events 10 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.
Psychiatric disorders Restlessness	5.3% 4/75 • Number of events 4 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	0.00% 0/72 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	2.7% 2/73 • Number of events 2 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	2.8% 2/71 • Number of events 2 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.	1.4% 1/73 • Number of events 1 • Up to Day 17 Safety analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug. One participant who was randomized to JNJ-42847922 10 mg dose group received 5 mg of JNJ-42847922. This participant was summarized under the 5 mg dose group for safety analyses.

Additional Information

Senior Director Clinical Development

Janssen Research & Development, LLC

Phone: 844-434-4210

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation.
Publication restrictions are in place

Restriction type: OTHER